Key Highlights

  • Adherium(ASX:ADR) reported RPM recurring subscription Revenue of $539,000, up 12.5% QoQ and marking the fifth consecutive quarter of record RPM revenue
  • Cumulative device activations reached 4,732 patients, growing at a 66% compound quarterly growth rate since September 2025
  • Customer cash receipts were $544,000, up 33% QoQ, with the AstraZeneca Arrival study payment of $257,917 received in October
  • The company partnered with Florida Lung subsequent to quarter end, expanding its clinical provider network

Adherium Limited(ASX:ADR) reported continued growth in its remote patient monitoring (RPM) Recurring Revenue during the September 2026 quarter, while positioning its Hailie Care platform for expansion into Value-Based Care contracts with US insurers.

The Melbourne-based digital health company achieved RPM recurring subscription accrual revenue of $539,000, up 12.5% from $479,000 in Q4 FY26 and representing a 381% increase over the September 2025 quarter. This marked the fifth consecutive quarter of record RPM revenue.

What Is Driving the Growth?

Cumulative RPM device shipments reached 6,392 as at 30 September 2026, up from 765 a year earlier, representing a 70% compound quarterly growth rate. Cumulative onboarded (activated) patients reached 4,732, growing at a 66% compound quarterly growth rate since September 2025.

Customer cash receipts were $544,000, up 33% QoQ from $408,000 in Q4 FY26. The AstraZeneca Arrival study Cash Receipt of $257,917 was received on 9 October 2026.

Interim CEO John Perry stated that the company is building a foundation through its RPM platform, creating recurring revenue streams, proprietary patient data and a growing body of clinical evidence. The company partnered with Florida Lung subsequent to quarter end.

How Is Adherium Building Clinical Evidence?

The company built on clinical evidence presented at the American Thoracic Society 2026 conference, including interim results from the independent Intermountain Health iCARE Study. A new 20-person feasibility study was signed with Lurie Children's Hospital to explore asthma digital tools in a paediatric population.

The RPM headcount was 57 at 30 September 2026, with 51.1 FTEs compared to 54.5 in Q4 FY26.

How Is Value-Based Care Being Pursued?

The RPM channel is central to demonstrating Adherium's ability to operate at scale and positioning the company for Value-Based Care (VBC) contracts with larger US insurers. The Hailie infrastructure — including the connected sensor platform, dedicated clinical team and longitudinal adherence data — is described as directly applicable to risk-bearing arrangements with health systems, payers and accountable care organisations.